ManageChatDiscover
415047

Enhanced Antimicrobial Activity and Cytotoxicity of Egyptian Streptomyces rochei RS2 through Optimized Fermentation Conditions: Insights from MTT Assay

Article

Last updated: 09 Apr 2025

OverviewSimilar Items

Subjects

-

Tags

Antimicrobial agents

Abstract

Background: The escalating prevalence of drug resistance and cancer necessitates the development of novel antimicrobial and anticancer agents. Objective: This study focuses on the isolation, characterization, and bioactivity assessment of actinomycetes-derived compounds with antimicrobial and cytotoxic potential. Methodology: Fifty-five soil samples from diverse regions in Egypt were initially identified based on morphological characteristics and the VITEK® 2 system. Three isolates were further confirmed using PCR and sequencing Results: Among these, three isolates (RS1, RS2, RS3) exhibited significant antimicrobial activity. Molecular characterization via PCR amplification and phylogenetic analysis confirmed RS2 as closely related to Streptomyces rochei. Optimization of fermentation conditions (pH 7, 28–31°C, 5–7 days incubation) significantly enhanced bioactive compound production. LC-MS analysis of RS2 crude extract identified antimicrobial compounds (Candicidin, Novobiocin, Erythromycin, Chloramphenicol) and anticancer agents (Mithramycin, anthracycline). The extract demonstrated robust antibacterial activity, with inhibition zones of 19 mm (E. coli), 21 mm (B. subtilis), 14 mm (S. aureus), and 12 mm (Pseudomonas sp.). Cytotoxicity assays revealed dose-dependent inhibition of HepG2 liver carcinoma cells, with an IC50 of 79.91 ± 0.24 µg/mL and 97.46% inhibition at 1000 µg/mL. Morphological changes in HepG2 cells indicated apoptosis induction at higherconcentrations. Conclusion: These findings underscore Streptomyces rochei RS2 as a promising source of novel antimicrobial and anticancer compounds, highlighting its potential for addressing drug-resistant pathogens and cancer therapy.

DOI

10.21608/ejmm.2025.361060.1482

Keywords

Streptomyces, Bioactive compound, Anticancer, antimicrobial activity

Authors

First Name

Reeham

Last Name

Shawqy

MiddleName

M.

Affiliation

Microbiology Department, Egyptian Drug Authority, Giza, Egypt

Email

reehamshawqy@icloud.com

City

cairo

Orcid

-

First Name

Khalid

Last Name

Abd El Ghany

MiddleName

I.

Affiliation

Microbiology Department, Egyptian Drug Authority, Giza, Egypt

Email

masterkhalid1@gmail.com

City

Giza

Orcid

-

First Name

Hanafy

Last Name

Hamza

MiddleName

A.

Affiliation

Department of Microbial Biotechnology, Genetic Engineering and Biotechnology Research Institute, University of Sadat City, Egypt

Email

hanafy.hamza@gebri.usc.edu.eg

City

alexandria

Orcid

-

First Name

Rateb

Last Name

Abbas

MiddleName

N.

Affiliation

Department of Microbial Biotechnology, Genetic Engineering and Biotechnology Research Institute, University of Sadat City, Egypt

Email

rateb.youssef@gebri.usc.edu

City

SADAT CITY

Orcid

-

Volume

34

Article Issue

2

Related Issue

51523

Issue Date

2025-04-01

Receive Date

2025-02-16

Publish Date

2025-04-01

Page Start

361

Page End

371

Print ISSN

1110-2179

Online ISSN

2537-0979

Article File

EJMM_Volume 34_Issue 2_Pages 361-371.pdf

PDF . 710.3kB

Link

https://ejmm.journals.ekb.eg/article_415047.html

Detail API

http://journals.ekb.eg?_action=service&article_code=415047

Order

415,047

Type

New and original researches in the field of Microbiology.

Type Code

2,038

Publication Type

Journal

Publication Title

Egyptian Journal of Medical Microbiology

Publication Link

https://ejmm.journals.ekb.eg/

MainTitle

Enhanced Antimicrobial Activity and Cytotoxicity of Egyptian Streptomyces rochei RS2 through Optimized Fermentation Conditions: Insights from MTT Assay

Details

Type

Article

Created At

09 Mar 2025